[1]LAFARO KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17.
|
[2]LIN CL,KAO JH.Risk stratification for hepatitis B viru related hepatocellular carcinoma[J].J Gastroenterol Hepatol,2013,28(1):10-17.
|
[3]GOH GB,CHANG PE,TAN CK,et al.Changing epidemiology of hepatocellular carcinoma in Asia[J].Best Pract Res Clin Gastroenterol,2015,29(6):919-928.
|
[4]DAVILA JA,KRAMER JR,DUAN Z,et al.Referral and receipt of treatment for hepatocellular carcinoma in United States veterans:effect of patient and nonpatient factors[J].Hepatology,2013,57(5):1858-1868.
|
[5]FORNERA,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
|
[6]TSUCHIYA N,SAWADA Y,ENDO I,et al.Potentiality of immunotherapy against hepatocellular carcinoma[J].World J Gastroenterol,2015,21(36):10314-10326.
|
[7]LIN ZX,RUAN DY,LI Y,et al.Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection[J].World J Gastroenterol,2015,21(38):10898-10906.
|
[8]LEE JH,LIM YS,YEON JE,et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology,2015,148(7):1383-1391.
|
[9] OHNISHI K,YOSHIOKA H,ITO S,et al.Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma[J].Hepatology,1998,27(1):67-72.
|
[10]ARIHARA F,MIZUKOSHI E,KITAHARA M,et al.Increase in CD14+HLA-DR-/lowmyeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis[J].Cancer Immunol Immunother,2013,62(8):1421-1430.
|
[11] BUTTERFIELD LH,RIBAS A,MENG WS,et al.T cell responses to HLA-A*0201 immunodominant peptides derived from alphafetoprotein in patients with hepatocellular cancer[J].Clin Cancer Res,2003,9(16Pt1):5902-5908.
|
[12]SCHMIDT N,FLECKEN T,THIMME R,et al.Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma a promising target for immunotherapy[J].Oncoimmunology,2014,3(9):e954919.
|
[13]HONG YP,LI ZD,ZHANG Q,et al.Immunotherapy for hepatocellular carcinoma:from basic research to clinical use[J].World JHepatol,2015,7(7):980-992.
|
[14] LI SQ,LIN J,QI CY,et al.GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice[J].Hepatogastroenterology,2014,61(130):278-284.
|
[15]XU H,GU N,LIU ZB,et al.NY-ESO-1 expression in hepatocellular carcinoma:a potential new marker for early recurrence after surgery[J].Oncol Lett,2012,3(1):39-44.
|
[16]FLECKEN T,SCHMIDT N,HILD S,et al.Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma[J].Hepatology,2014,59(4):1415-1426.
|
[17]BUONAGURO L,PETRIZZO A,TAGLIAMONTE M,et al.Challenges in cancer vaccine development for hepatocellular carcinoma[J].JHepatol,2013,59(4):897-903.
|
[18] LANG J,DING T,GUO ZW,et al.Expression pattern of tumour-associated antigens in hepatocellular carcinoma:association with immune infiltration and disease progression[J].Br J Cancer,2013,109(4):1031-1039.
|
[19]GEHRING AJ,HO ZZ,TAN AT,et al.Profile of tumor antigenspecific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma[J].Gastroenterology,2009,137(2):682-690.
|
[20]ZERBINI A,PILLI M,SOLIANI P,et al.Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma[J].J Hepatol,2004,40(1):102-109.
|
[21]WEON JL,POTTS PR.The MAGE protein family and cancer[J].Curr Opin Cell Biol,2015,37:1-8.
|
[22]CARULLI L,ANZIVINO C.Telomere and telomerase in chronic liver disease and hepatocarcinoma[J].World J Gastroenterol,2014,20(20):6287-6292.
|
[23] MIZUKOSHI E,NAKAMOTO Y,MARUKAWA Y,et al.Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma[J].Hepatology,2006,43(6):1284-1294.
|
[24]MIZUKOSHI E,NAKAGAWA H,KITAHARA M,et al.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma[J].Cancer Lett,2015,364(2):98-105.
|
[25] AREF AM,HOA NT,GE L,et al.HCA519/TPX2:a potential T-cell tumor-associated antigen for human hepatocellular carcinoma[J].Onco Targets Ther,2014,7:1061-1070.
|
[26] JOSEFOWICZ SZ,LU LF,RUDENSKY AY.Regulatory T cells:mechanisms of differentiation and function[J].Annu Rev Immunol,2012,30:531-564.
|
[27] MOON BI,KIM TH,SEOH JY.Functional Modulation of Regulatory TCells by IL-2[J].PLo S One,2015,10(11):e0141864.
|
[28]ZHAO HQ,LI WM,LU ZQ,et al.Roles of Tregs in development of hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2014,20(24):7971-7978.
|
[29]SCHRADER J.The role of MDSCs in hepatocellular carcinoma:in vivo veritas?[J].J Hepatol,2013,59(5):921-923.
|
[30] ILKOVITCH D,LOPEZ DM.The liver is a site for tumor induced myeloid-derived suppressor cell accumulation and immunosuppression[J].Cancer Res,2009,69(13):5514-5521.
|
[31]HOECHST B,VOIGTLAENDER T,ORMANDY L,et al.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor[J].Hepatology,2009,50(3):799-807.
|
[32] MEDINA-ECHEVERZ J,EGGER T,HAN MJ,et al.Hepatic myeloid-derived suppressor cells in cancer[J].Cancer Immunol Immunother,2015,64(8):931-940.
|
[33]FUJIWARA K,HIGASHI T,NOUSO K,et al.Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma[J].J Gastroenterol Hepatol,2004,19(10):1121-1127.
|
[34]BERTINO G,DEMMA S,ARDIRI A,et al.Hepatocellular carcinoma:novel molecular targets in carcinogenesis for future therapies[J].Biomed Res Int,2014,2014:203693.
|
[35] HERBST RS,SORIA JC,KOWANETZ M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.
|
[36]ALI MY,GRIMM CF,RITTER M,et al.Activation of dendritic cells by local ablation of hepatocellular carcinoma[J].J Hepatol,2005,43(5):817-822.
|